Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11696381 | 1.00 | FAAH (0.55) | FAAHGAAALDH1A1LMNACYP2C9 | |
| SCHEMBL14573137 | 1.00 | FAAH (0.55) | FAAHGAAALDH1A1LMNACYP2C9 | |
| SCHEMBL12753930 | 0.92 | GAA (0.61) | GAAALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL1876276 | 0.92 | GAA (0.61) | GAAALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL2451978 | 0.89 | GAA (0.58) | FAAHGAAALDH1A1LMNACYP2C9 | |
| SCHEMBL2451979 | 0.89 | GAA (0.58) | FAAHGAAALDH1A1LMNACYP2C9 | |
| SCHEMBL2451656 | 0.88 | GAA (0.57) | FAAHGAAALDH1A1LMNACYP2C9 | |
| SCHEMBL2451388 | 0.88 | GAA (0.57) | FAAHGAAALDH1A1LMNACYP2C9 | |
| SCHEMBL11693886 | 0.88 | FAAH (0.53) | FAAHGAAALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2451659 | 0.88 | GAA (0.57) | FAAHGAAALDH1A1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4018507-A | Liquid crystal device, composition therefor, and method for preparing the composition | AMERICAN MICRO-SYSTEMS, INC. (US) | 1977-04-19 | — | — | US | claimed |
| EP-2414326-B1 | INTERMEDIATES IN THE PREPARATION OF 1,4-DIPHENYL AZETIDINONE | LUPIN LTD (IN) | 2017-12-20 | — | — | EP | disclosed |
| US-9518014-B2 | Process for synthesis of ezetimibe and intermediates used in said process | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-12-13 | — | — | US | disclosed |
| EP-2876102-B1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2016-12-07 | — | — | EP | disclosed |
| US-20150166479-A1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2876102-A1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2015-05-27 | — | — | EP | disclosed |
| US-9040688-B2 | Intermediates in the preparation of 1,4-diphenyl azetidinone | LUPIN LIMITED (IN) | 2015-05-26 | — | — | US | disclosed |
| WO-2015039675-A1 | NOVEL PROCESS FOR THE PREPARATION OF EZETIMIBE INTERMEDIATES | PHARMATHEN S.A. (GR) | 2015-03-26 | — | — | WO | disclosed |
| WO-2012173504-A2 | METHOD FOR SYNTHESIS OF THE SUBSTITUTED AZETIDINONES AND INTERMEDIATES FOR THEIR SYNTHESIS | Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012155932-A1 | IMPROVED PROCESS FOR THE PREPARATION OF EZETIMIBE | PHARMATHEN S.A. (GR) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012076030-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE COMPOUNDS USEFUL IN THE PREPARATION OF EZETIMIBE | PHARMATHEN S.A. (GR) | 2012-06-14 | — | — | WO | disclosed |
| US-20120029185-A1 | NOVEL INTERMEDIATES IN THE PREPARATION OF 1,4-DIPHENYL AZETIDINONE | LUPIN LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| WO-2010113182-A1 | INTERMEDIATES IN THE PREPARATION OF 1,4-DIPHENYL AZETIDINONE | LUPIN LIMITED (IN) | 2010-10-07 | — | — | WO | disclosed |
| US-20090227786-A1 | PROCESSES FOR PREPARING INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF EZETIMIBE | MEDICHEM S.A. (ES) | 2009-09-10 | — | — | US | disclosed |
| US-7544667-B2 | Hypocholesterolemic compounds | LIPIDEON BIOTECHNOLOGY AG (CH) | 2009-06-09 | — | — | US | disclosed |
| US-20070275909-A1 | Useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels; carbohydrate-containing pyrazolidinone or oxazolidinone derivatives, for example | LIPIDEON BIOTECHNOLOGY AG (CH) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166479-A1 | PROCESS FOR SYNTHESIS OF EZETIMIBE AND INTERMEDIATES USED IN SAID PROCESS | HMGCR, COASY, APOB | FAAH 2243/4885GAA 319/4885ALDH1A1 268/4885 |
| US-20090227786-A1 | PROCESSES FOR PREPARING INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF EZETIMIBE | PCSK9, HMGCR, NPC1L1 | FAAH 847/4885GAA 292/4885ALDH1A1 257/4885 |
| US-20120029185-A1 | NOVEL INTERMEDIATES IN THE PREPARATION OF 1,4-DIPHENYL AZETIDINONE | NDUFV2, DHPS, CYP1B1 | FAAH 4302/4885GAA 2324/4885ALDH1A1 123/4885 |
| US-20070275909-A1 | Useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels; carbohydrate-containing pyrazolidinone or oxazolidinone derivatives, for example | PCSK9, APOB, HMGCR | FAAH 3338/4885GAA 1440/4885ALDH1A1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.